Pharmacological Mechanisms of Low-intensity Focused Ultrasound for Motor Cortex Neuroplasticity

NCT ID: NCT04923659

Last Updated: 2025-08-03

Basic Information

• Recruitment Status: ACTIVE_NOT_RECRUITING
• Clinical Phase: EARLY_PHASE1
• Total Enrollment: 20 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2021-05-25
• Study Completion Date: 2026-05-31

Brief Summary

Low-intensity focused ultrasound (LIFUS) has been shown to be an effective and safe non-invasive brain stimulation technique, capable of reaching greater brain depth and a greater spatial resolution than other brain stimulation tools. Its use as a potential clinical tool for treatment of neurological disorders is reliant on an understanding of its mechanisms of action. Although it has been shown to induce immediate (online) and prolonged (offline) changes in plasticity in the motor cortex, researchers have not studied its effects on neurotransmitter receptors and ion channels responsible for neuronal signaling in humans. The purpose of this study is to explore the effects of online and offline LIFUS stimulation in tandem with administration of various brain-active drugs, to elucidate the effects of this technique on specific cortical receptors and channels. 20 healthy, screened subjects will be recruited to participate in 5 sessions in-lab. Each session will represent the double-blinded administration of four known and studied pharmacological agents known to safely induce changes in the motor cortex, as well as a placebo. Investigators will use carbamazepine (sodium channel blocker), lorazepam (GABAA positive allosteric modulator), nimodipine (calcium channel blocker), and dextromethorphan (glutamate N-Methyl-D-aspartate receptor antagonist). Single- and paired-pulse transcranial magnetic stimulation (TMS) measures will be recorded for online LIFUS before and after drug intervention, and induction of offline LIFUS during placebo will be compared with its induction following the various drug interventions. Investigators predict that due to the differential effects of online and offline LIFUS on motor parameters, the mechanisms in which it alters the receptors and channels of interest will also be differentially modulated.

Detailed Description

In the current study investigators aim to describe how common neurotransmitter receptors and ion channels in the brain, particularly the motor cortex, are dynamically involved in the mechanisms generated by LIFUS. By selectively modulating the activity of these receptors and channels with previously studied and known drugs, it can be empirically determined how common components of signal propagation and prolonged neuroplasticity are being affected by the sonication waves induced by LIFUS. This will be done through baseline recording of FUS-induced neuroplasticity, and then compared within-subject to FUS-induced neuroplasticity after administration of pharmacological agents of interest. Random double-blinded administration of four drugs and a placebo will ensure that results are accurate and reduce any effects of expectation. Its predicted that online FUS will lead to a reduction in motor excitation and an increase in intracortical inhibition, and offline FUS will lead to an increase in motor excitation, an increase in intracortical facilitation, and a reduction in intracortical inhibition. Its predicted that drugs of interest to similarly replicate previous work; that is, carbamazepine, lorazepam, dextromethorphan, and nimodipine will all reduce cortical excitation and increase intracortical inhibition compared to placebo. Its predicted that carbamazepine, lorazepam, nimodipine and dextromethorphan will all further reduce motor excitation in conjunction with online FUS in an additive manner, compared to placebo. Its predicted that carbamazepine will have no effect on the prolonged effects of offline FUS on the motor cortex, but that lorazepam, nimodipine, and dextromethorphan will all interfere with the offline effects of FUS on motor cortex, compared to placebo.

Conditions

Low Intensity Focussed Ultrasound

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: BASIC_SCIENCE
• Blinding Strategy: NONE

Study Groups

LIFUS

Low Intensity Focussed ultrasound.

Group Type: EXPERIMENTAL

Carbamazepine

Intervention Type: DRUG

600 mg reconstituted as one table. Administered once

Lorazepam

Intervention Type: DRUG

2.5 mg mg reconstituted as one table. Administered once

Dextromethorphan

Intervention Type: DRUG

150 mgmg reconstituted as one table. Administered once

Nimodipine

Intervention Type: DRUG

30 mg reconstituted as one table. Administered once

Placebo

Intervention Type: DRUG

Administered once

Interventions

Carbamazepine

600 mg reconstituted as one table. Administered once

Intervention Type: DRUG

Lorazepam

2.5 mg mg reconstituted as one table. Administered once

Intervention Type: DRUG

Dextromethorphan

150 mgmg reconstituted as one table. Administered once

Intervention Type: DRUG

Nimodipine

30 mg reconstituted as one table. Administered once

Intervention Type: DRUG

Placebo

Administered once

Intervention Type: DRUG

Other Intervention Names

Tegretol; Ativan; Robitussin; Nimotop; Sugar

Eligibility Criteria

Inclusion Criteria

• Right-handed healthy subjects between the ages of 18-65 will be included for recruitment.

Exclusion Criteria

• Diagnosed with any gait or postural disorders
• Major neurological disease or disorder
• Major musculoskeletal or nerve disorder, or disorder of hands, wrists and upper limbs
• History of stroke or seizure
• Diagnosed with dementia
• Diagnosed with myasthenia gravis or acute narrow angle glaucoma
• Has intracranial implant(s) or device(s)
• Has an implanted cardiac pacemaker or implantable cardioverter-defibrillator (ICD)
• Presence of metal implanted in body that is contraindicated in TMS
• Caffeine or chocolate consumption 1-2 hours before study sessions
• Consumption of grapefruit juice 24 hours before study sessions
• Alcohol consumption 24 hours before study sessions
• Pregnancy*
• Major depression/psychiatric disorder that in the opinion of the Investigator will affect patient's understanding of study procedures and willingness to abide by all procedures during the course of the study
• Regular usage of CNS active drugs or calcium channel blockers during or up to 2 weeks before participating in the study**
• Is on antipsychotics, marijuana, or other recreational drugs (including tobacco) that affect the nervous system
• Major cardiac, hematopoietic, liver, or kidney disease or infection
• Treated hypertension
• Hypersensitivity to benzodiazepines
• Hypersensitivity to calcium channel blockers
• Hypersensitivity to antitussives
• Hypersensitivity to anticonvulsants
• Regular usage of androgens, antibiotics, antifungals, antivirals, cardiovascular/gastrointestinal drugs, muscle relaxants, and platelet aggregation inhibitors during or up to 2 weeks before participating in the study

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 65 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

University Health Network, Toronto

OTHER

Sponsor Role: lead

Responsible Party

Robert Chen

Senior Neurologist and Scientist

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Robert Chen, MBBS

Role: PRINCIPAL_INVESTIGATOR

University Health Network, Toronto

Locations

Toronto Western Hospital

Toronto, Ontario, Canada

Countries

Canada

Other Identifiers

YS609220

Identifier Type: -

Identifier Source: org_study_id